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Abstract 
The neuroprotective actions of kynurenic acid (KYNA) and its derivatives in several neurodegenerative disorders 
(characterised by damage to the cerebral endothelium and to the blood-brain barrier (BBB)) are well established. 
Cell-extracellular matrix (ECM) adhesion is supposedly involved in recovery of impaired cerebral endothelium 
integrity (endothelial repair).  
The present work aimed to investigate the effects of KYNA and its synthetic derivatives on cellular behaviour 
(e.g. adhesion and locomotion) and on morphology of the GP8 rat brain endothelial cell line, modeling the BBB 
endothelium. The effects of KYNA and its derivatives on cell adhesion were measured using an impedance-based 
technique, the xCELLigence SP system. Holographic microscopy (HolomonitorTM M4) was used to analyse both 
chemokinetic responses and morphometry.  
The GP8 cells proved to be a suitable model cell line for investigating cell adhesion and the locomotion modulator 
effects of kynurenines. KYNA enhanced cell adhesion and spreading, and also decreased the migration/motility 
of GP8 cells at physiological concentrations (10-9 and 10-7 mol/L). The derivatives containing an amide side chain 
at the C2 position (KYNA-A1 and A2) had lower adhesion inducer effects compared to KYNA. All synthetic 
analogues (except KYNA-A5) had a time-dependent inhibitory effect on GP8 cell adhesion at a supraphysiological 
concentration (10-3 mol/L). The immobilization promoting effect of KYNA and the adhesion inducer activity of 
its derivatives indicate that these compounds could contribute to maintaining or restoring the protective function 
of brain endothelium; they also suggest that cell-ECM adhesion and related cell responses (e.g. migration/motility) 
could be potential new targets of KYNA. 
 
Keywords: Endothelial repair, Kynurenic acid, Holographic microscopy, Impedimetry, Synthetic kynurenines, 
Brain endothelial cell 
 
Chemical compounds studied in this article: Kynurenic acid (PubChem CID: 3845), L-Kynurenine (Pubchem 
CID: 161166)  
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1. Introduction 
L-kynurenine (KYN) and kynurenic acid (KYNA) are endogenous metabolites of tryptophan. The kynurenine 
pathway is the main pathway for breaking down tryptophan in the brain; it is also expressed to a varying degree in 
astrocytes, neurons, glia, macrophages, endothelial cells and dendritic cells. Approximately 95% of tryptophan is 
believed to convert to KYN by two catalytic steps: The first is a catalysis by either tryptophan- or indoleamine 
2,3-dioxygenases (TDO or IDO-1, IDO-2) and the second is mediated by formamidase (Fig. 1) (Vecsei et al. 2013). 
KYN serves as a key molecule between neurotoxic and neuroprotective metabolites since it can be metabolised 
via three distinct pathways to form (i) 3-hydroxy-L-kynurenine, (ii) anthranilic acid and (iii) kynurenic acid by the 
action of kynurenine 3-monooxygenase, kynureninase and kynurenine aminotransferases (KATs), respectively. 
Four subtypes of KATs (KAT I, II, III and IV) have been identified and all of them showed transamination activity 
towards KYN, leading to synthesis of KYNA; however, there are differences in their substrate specificity, their 
pH profiles and their contribution to KYNA formation in the brain (Han et al. 2010). 3-hydroxy-L-kynurenine can 
be further transformed, leading to the formation of quinolinic acid via intermediates that include 3-
hydroxyanthranillic acid. Quinolinic acid and its intermediates are known neurotoxic compounds; they generate 
free radicals, oxidative stress, lipid peroxidation and subsequently excitotoxicity due to excitatory amino acid 
receptors (Moroni et al. 2012; Vecsei et al. 2013). In contrast, KYNA has been widely shown to have a 
characteristic neuroprotective effect and has been proven to act protectively amidst degenerative processes 
(Alzheimer’s- (Zwilling et al. 2011), Huntington’s- (Beal et al. 1990; Zadori et al. 2011) and Parkinson’s diseases 
(Ogawa et al. 1992; Silva-Adaya et al. 2011)). Furthermore, KYNA’s actions are also implicated in migraines 
(Vecsei et al. 2013), as well as in inflammatory (Varga et al. 2010) and immunological (Mandi and Vecsei 2012; 
Tiszlavicz et al. 2011) mechanisms.  
KYNA has been described as a potential blocker of endogenous excitatory amino acid receptors (e.g. 
ionotropic glutamate receptors): glycine binding site of N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA), kainite receptors (Perkins and Stone 1982; Prescott et al. 2006; Wu et 
al. 1995) and the α-7-nicotinic acetylcholine (nACh) receptor (Hilmas et al. 2001; Zwilling et al. 2011). However, 
interesting dose-dependent effects of KYNA were revealed in in vitro electrophysiological examinations of young 
rat hippocampi. It was confirmed that KYNA (referred to as Janus-face molecule) exerts inhibitory effects at 
micromolar concentrations, while at nanomolar concentrations, it facilitates field excitatory postsynaptic potentials 
(Rozsa et al. 2008). Furthermore, KYNA acts as an agonist of the G-protein-coupled orphan receptor (GPR35), 
which can contribute to decreased glutamate as well as to pro-inflammatory mediator release from glia and immune 
cells by means of attenuated cAMP and intracellular Ca2+ concentration. The exact role of GPR35 in the nervous 
system remains unknown, but it has been demonstrated that the KYNA-GPR35 relationship is important in certain 
neurodevelopmental processes (Cosi et al. 2011).  
The above-mentioned pathological conditions, where the alteration of the kynurenine pathway was observed, 
such as inflammation (e.g. multiple sclerosis), neurodegeneration (e.g. Alzheimer’s disease) and cerebral ischemia 
(e.g. stroke); are characterised by disruption of the functional/structural integrity of brain endothelial cells and 
impairment in the function of the blood-brain barrier (BBB) (del Zoppo and Milner 2006; Lyros et al. 2014; 
Persidsky et al. 2006).  
From the point of view of barrier function, the brain endothelial cells are considered to be the most important 
cell type of the neurovascular unit; consisting of astrocytes, pericytes, neurons and extracellular matrix (ECM) of 
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the basement membrane (Persidsky et al. 2006; Wilhelm et al. 2011). The permeability of cerebral endothelial 
cells is based mainly on two structures: (i) inter-endothelial junctions (tight and adherent junctions), (ii) cell-ECM 
interactions involving integrins, dystroglycans of the endothelial cells and (iii) the constituent components of the 
intact basement membrane (del Zoppo and Milner 2006). Cell-ECM interactions contribute to ensuring the 
morphology and function of cerebral endothelial cells in quiescent state and to maintaining the BBB by (i) 
regulating key cellular processes (proliferation, differentiation and migration); (ii) modifying VE-cadherin 
junctions and consequently endothelial permeability, as well as (iii) anchoring the endothelial cells in place and 
regulating their migration (Baeten and Akassoglou 2011; del Zoppo and Milner 2006; Persidsky et al. 2006). The 
components of the basement membrane (e.g. collagen IV, laminin, perlecan), which together represent the other 
side of cell-ECM interaction, also regulate endothelial function by (i) interacting with matrix adhesion receptors, 
(ii) modulating the availability of growth factors and (iii) increasing transendothelial electrical resistance (barrier 
properties) (Baeten and Akassoglou 2011). 
During neuropathological changes, initial disturbances in cerebral microcirculation, pro-inflammatory and 
autoimmune conditions lead to endothelial/BBB dysfunction and increased permeability (Lyros et al. 2014; Vecsei 
et al. 2013). As an early consequence, the endothelium becomes dysfunctional and reactive oxygen species (ROS) 
are generated; and the expression of adhesion molecules and chemokines induce the recruitment of leukocytes 
(Baeten and Akassoglou 2011; Kelleher and Soiza 2013). The prolonged presence of oxidative/ inflammatory 
factors can result in changes to or loss of tight junctions and integrins (e.g. β1, αv, α6 integrins), leading to 
senescence and detachment-mediated cell death (anoikis) (Baeten and Akassoglou 2011; del Zoppo and Milner 
2006). These changes together contribute to secondary inflammation, further breakdown of the BBB with leakage 
of plasma proteins and neurotoxic substances, or to thrombus formation by exposure of subendothelial tissues 
(Baeten and Akassoglou 2011; Kelleher and Soiza 2013; Lyros et al. 2014).  
Endothelial cells have regenerative capacity, helping to restore normal structure and function. There are two 
main kinds of endogenous endothelial repair process (Fig. 2): (i) Proliferation and migration of endothelial cells 
surrounding the lesion, leading to rapid re-endothelization; the repair capacity in this case is limited; (ii) 
Incorporation of circulating endothelial progenitor cells as an alternative mechanism to replacing lost and/or 
injured endothelial cells (Deanfield et al. 2007). The capacity of endogenous endothelial repair mechanisms is 
dependent on several factors that can increase proliferation (e.g. vascular endothelial growth factor (VEGF)) and 
migration (e.g. stromal cell-derived factor 1 (SDF-1) chemokine; nitric oxide) of the endothelial cells, or can 
upregulate the expression of several cell-ECM adhesion molecules (e.g. α5β1 integrin – fibronectin receptor, α4 
and β2 integrin, E-selectin ligand); these were shown to be involved in the homing of endothelial progenitor cells 
or in local endothelial repair (Fig. 2) (Besler et al. 2008; Deanfield et al. 2007; Zampetaki et al. 2008).  
A considerable amount of literature indicates that KYNA can also have remarkable functions in endothelial 
cells. Wejksza and her co-workers have revealed the presence of KAT I and KAT II as well as de novo synthesis 
of KYNA from KYN in cultured bovine aortic endothelial cells. Endothelial cells are able to regulate the 
concentration of kynurenines in the central nervous system (CNS) by taking up KYN and converting it to KYNA 
(Wejksza et al. 2004). It is assumed that the expression changes of IDO in endothelial cells by inflammatory 
mediators may regulate vascular tone and subsequently neuronal activity, neurodegeneration and cognition. There 
is evidence to suggest that the KYN may be secreted from the basolateral pole of endothelial cells, gaining direct 
access to the brain (Owe-Young et al. 2008); this is especially important in conditions with a compromised BBB 
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(Kandanearatchi and Brew 2012). It is also suggested that KYNA may have modulatory effects on the function of 
the BBB. The administration of KYNA could reduce the number of KCl-induced cortical spreading depression 
(CSD) waves and in parallel decrease CSD-associated permeability of the BBB (Oláh et al. 2013). 
To study the function and the molecular and cellular mechanisms of BBB endothelium, several co-culture 
techniques (including primary brain endothelial cells) have been developed (Dehouck et al. 1990). However, these 
experimental BBB systems have some drawbacks: (i) The phenotypic instability of primary cerebral endothelial 
cultures, (ii) the difficulty in eliminating all non-endothelial cell contaminants and (iii) and insufficiently high 
throughput required for toxicity studies (Culot et al. 2008; Roux and Couraud 2005). The different immortalised 
brain endothelial cell lines (e.g. GP8 (Greenwood et al. 1996), GPNT (Regina et al. 1999) or hCMEC/D3 (Weksler 
et al. 2005)) were shown to be powerful and simplified alternatives of primary cerebral endothelial cells for 
neurotoxicity and permeability studies (Wilhelm et al. 2011). In our current study, the GP8 rat brain endothelial 
cell line was used, as it retains both cerebral endothelial morphology (cobblestone shape) and the expression of 
adhesion molecules (e.g. ICAM-1 or PECAM-1), transporters (e.g. P-glycoprotein) (Greenwood et al. 1996; Roux 
and Couraud 2005; Wilhelm et al. 2011) and vasoactive substances (e.g. arachidonic acid metabolites) (Kis et al. 
1999) which are considered to be characteristic for BBB endothelium.  
The above mentioned findings indicate that influential endothelial cell-ECM adhesion and locomotion may 
be involved in the pharmacological effects of KYNA and its derivatives. 
In the present work, our main objectives were:  
i) To characterise the cell adhesion/morphology and locomotion of the GP8 brain endothelial cell line 
exposed to KYNA by label-free and real-time methods: impedimetry and holographic imaging. 
ii) To characterise and compare the cell-ECM adhesion modulator effects of different synthetic 
kynurenines in the GP8 cell line. 
 
2. Material and methods 
2.1 Kynurenic acid and its analogues 
KYN and KYNA were obtained from Sigma Aldrich (Steinheim, Germany). The KYNA-analogues (Table 1) 
were synthesized and tested at the laboratory of the Institute of Pharmaceutical Chemistry, University of Szeged, 
according to procedures described earlier (Demeter et al. 2012; Fülöp et al. 2012; Nagy et al. 2011). All KYNA-
analogues contain a cationic center in their side chains. 
KYNA and KYN analogues were dissolved in a 1:1 mixture of DMEM and F12 media (pH=7.4) in order to 
prepare stock solutions of 10-2 mol/L concentration. The stock solutions were further diluted to the final 
concentrations of 10-9, 10-7, 10-5 and 10-3 mol/L, in complete medium used for cell culturing (see below). The 
selection of tested concentrations was based on the Janus-face character of KYNA (Rozsa et al. 2008), as well as 
on the plasma concentrations of KYNA (e.g. normal conditions, inflammation) (Mandi and Vecsei 2012). The 
negative control was the adequate volume of complete cell culture medium without test compounds.  
 
2.2 Cell culturing 
Cell adhesion induced by KYNA and its derivatives was investigated on the GP8 rat brain endothelial cell 
line (Greenwood et al. 1996).  
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The cells were maintained in a T25 flask (Orange Scientific, Braine-l'Alleud, Belgium), coated previously 
with rat tail collagen for 60 min at room temperature. The cells were passaged twice a week in a 1:1 mixture of 
DMEM and F12 (Sigma Ltd. St. Louis, MO, USA) containing 10% foetal bovine serum (Lonza Group Ltd., 
Switzerland), L-glutamine (2 mmol/L), 0.1 mg/mL heparin (Teva, Debrecen, Hungary), 1 ng/mL basic fibroblast 
growth factor (Roche Applied Science, Indianapolis, IN, USA), 100 µg/mL penicillin/streptomycin (Gibco® / 
Invitrogen Corporation, New York, NY, USA).  
 
2.3 Cell adhesion assay 
The effects of KYNA and its analogues on adhesion of the GP8 cells were assessed using the xCELLigence 
SP System (Roche Applied Science, Indianapolis, IN, USA), which measured the change in impedance of gold 
microelectrodes integrated on the bottom of a tissue culture plate (E-plate) in real-time manner. More cells attached 
to the electrode, or higher spreading of cells creates a larger increase in impedance. Changes in impedance are 
represented by the Cell Index (CI). The CI is a relative and dimensionless value, calculated by the following 
formula:  
CI =
(Z୧ − Z଴)
F୧
 
 
where Z୧ is the impedance at an individual point of time during the experiment, Z଴ is the impedance at the start of 
the experiment, and F୧ is a constant depending on the frequency (Fଵ଴୩ୌ୸ = 15). 
During the characterization of the adhesion behaviour of GP8 rat brain endothelial cells, two types of ECM 
substrate (collagen, mixture of gelatin and fibronectin) were applied. In this experiment, the surface of the 
electrodes was coated either with rat tail collagen for 60 min at room temperature, or with a mixture of 1 μg/cm2 
human fibronectin (Chemicon® International Inc., Temecula, Canada) in 0.1% gelatin (Sigma Ltd. St. Louis, MO, 
USA) for 20 min incubation at 4°C. The uncoated surface served as a control. After the coating, a background 
measurement was performed by adding 100 µL of complete culture medium and then recording the cell index for 
1 h to gain constant background impedance curves. The cells were then added to the well at the final concentration 
of 104 cells per well. The attachment and spreading of the model cell were characterised by a time course study of 
Delta CI values. Delta CI refers to the difference of CI value at the time point of cell inoculation and the CI value 
at the given point in time. The adhesive capacity of the cells was described by the slope of Delta CI, calculated at 
a 3 hour time interval (from the inoculation of the cells to the maximum of CI increase). The slope values were 
expressed as a percentage of the control.  
In order to measure the adhesion modulator effects of KYNA and its derivatives, the electrodes were coated 
with human 1 μg/cm2 human fibronectin (Chemicon® International Inc., Temecula, Canada) in 0.1% gelatin 
(Sigma Ltd. St. Louis, MO, USA). The solutions of KYNA derivatives at the final concentrations of 10-9, 10-7, 10-
5, 10-3 mol/L were added to the wells, and GP8 cells were applied at a concentration of 104 cells/well. Compound-
free wells served as a control. The adhesion of the GP8 cells was monitored every 20 sec for 24 h at 10 kHz.  
The Delta CI values obtained at the 5, 10 and 15 h for each concentration of kynurenine were normalized to the 
untreated control and were given as Norm. Delta CI (Normalized Delta Cell Index) as a percentage. 
 
2.4 Digital holographic microscopy 
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The HolomonitorTM M4 microscope (Phase Holographic Imaging AB, Lund, Sweden) was used for imaging 
and tracking both GP8 cell movement and morphological changes induced by KYNA. This technique provides 
quantitative and long-term kinetic cellular analysis without any cell labelling. The principle behind this method is 
the detection of the phase shift of the probing laser light transmitting or reflecting through a cell sample and 
comparison to the reference light (Persson et al. 2010; Peter et al. 2015).  
The GP8 cells were seeded (2.5 x 105 cells) on a Petri dish (diameter: 35 mm), coated with 0.1% gelatin 
containing human 1 μg/cm2 human fibronectin and allowed to adhere for 24 h. After automatic calibration of the 
background and microscope objective (20x), one field of each sample was focused on by the digital autofocus 
feature. The cells were then treated with KYNA at the final concentrations of 10-9, 10-7 mol/L, or with an equivalent 
volume of culture medium, and captured every 30 sec for 2 h.  
For the evaluation, at each time-lapse sequence, 50 cells were identified and selected by minimum error histogram-
based threshold algorithm of the software (HoloStudio M4 2.6.2). By tracking the cells, the movement and 
morphological changes were automatically analysed over time.  
Cell movement, representing the chemokinetic effects of KYNA, was characterised by measurement of the 
following parameters: (i) migration (shortest distance between the starting point and the end point); (ii) motility 
(actual path of a cell from the starting point to the end point) and (iii) motility speed (ratio of actual path to time).  
For the morphometry analysis, different basic and complex morphological parameters were displayed as a 
function of time. The (i) area, (ii) thickness and (iii) volume were grouped as basic metrics, while the more complex 
parameters relating to cell shape were: (iv) The eccentricity (how elongated a cell is comparing to a circle), (v) the 
Hull convexity (how different the 3D shape of a cell is compared to a perfect convex shape), (vi) the irregularity 
(how different the circumference of a cell is compared to the circumference of a perfect circle) and (vii) roughness 
(smoothness/roughness of a cell). The smoothness/roughness of a cell, characterised by the roughness parameter, 
indicates the viability of the treated cell (Lajkó et al. 2015; Tóth et al. 2014).  
 
2.5 Statistical evaluation of data 
The Delta CI and slope values were calculated using the integrated software (RTCA 1.2, Roche Applied 
Science, Indianapolis, IN, USA) of the xCELLigence SP System. The results of the experiments with holographic 
microscope were evaluated using the HolostudioTM M4 2.6.2 program. For further analysis of the data, the Origin 
Pro8.0 (OriginLab Corporation, Northampton, MA, USA) statistical program was used. Data shown in the figures 
represent mathematical averages of three parallels and ±SD values. Statistical analysis was done by application of 
ANOVA using Origin Pro8.0. Tukey’s post-hoc test was used to assess the statistical significance among means. 
The levels of significance are shown as follows: *: p<0.05; **: p<0.01; ***: p<0.001. 
 
3. Results 
3.1 Cell adhesion behaviour of GP8 endothelial cells 
Both the collagen and gelatin+fibronectin coatings elicited an increased adhesion of the cells compared to 
the control (uncoated surface), but with different activity. The attachment rate of the GP8 cells proved to be higher 
with gelatin+fibronectin (308.5%, p = 0.00011) compared to collagen (132.1%, p = 0.0196). However, the 
difference was significant only in the first 5 hours of the measurements; it then gradually decreased to level of 
collagen-induced adhesion. This pattern of adhesion curve suggests that the initial spreading of the cells – 
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accompanied by a rapid, strong adhesion – is followed by a partial release of focal contacts. In contrast, the collagen 
coating resulted in a gradual increase of adhesion whereby spreading then reached a constant level (plateau phase) 
(Fig. 3/a, b). 
 
3.2 Cell adhesion modulator effect of kynurenic acid and its analogues 
Following the characterization of cell adhesion in GP8 cells, KYNA and KYN – as reference molecules – 
and 4 KYNA analogues (Table 1) were investigated for their effects on cell adhesion of GP8 cells on a 
gelatin+fibronectin-coated surface.  
In Fig. 4, the effects of KYNA and KYN were shown as a function of time (Fig. 4aa, ba) and concentration 
(Fig. 4ab, bb). The concentration-dependent effects of KYNA analogues are shown in Fig. 5 and their time-
dependent effects are shown in Online Resource 1. The effects of KYNA derivatives were investigated in different 
experiments using an internal control. Although the experimental conditions (coating, cell number, maximum 
volume/well and cells with consecutive passage number) were the same in each case, the maximum Delta CI value 
of the control varied between 1.05 (Fig. 3), 1.7 (Fig. 4aa; Online Resource 1) and 1.45 (Fig 4ba; Online Resource 
1) in the time course cell adhesion studies. In the Delta CI vs. Time graphs (Fig. 3a; Fig. 4aa, ba; Online Resource 
1), the time-dependent effect of KYNA derivatives are depicted and compared to the identical control. The 
different adhesion kinetics of GP8 cells could also be observed in Fig 3a and Fig 4aa, ba. Some examples of this 
kind of variation in adhesion kinetics of same cells between experiments are noted in literature (Backer et al. 2017; 
Leurs et al. 2012; Tang et al. 2015). The real-time impedance based measurements that can record the impedance 
with the given time interval are sensitive enough to detect the actual status of the cells, which could not otherwise 
be revealed by classical end-point assay. 
To determine that KYNA and its derivatives induced CI change was a result of endothelial reaction and not 
due to the physico-chemical properties of the compounds (e.g. acidity), some cell-free wells were loaded with only 
the tested ligands at 10-3M concentration. KYNA derivatives themselves did not cause any significant change in 
CI values.  
KYNA itself was able to increase the adhesion of GP8 cells through an inversely proportional concentration 
dependent manner, with maximum effect at a concentration of 10-9 mol/L. This positive effect of KYNA was more 
pronounced as time progressed (15 h: 129.5%, p = 0.039) (Fig. 4aa, ab). KYN itself differs considerably in structure 
from KYNA and failed to exert a cell adhesion modulator effect; it had neutral effects throughout the entire 
concentration range, even at the highest concentration of 10-3 mol/L (Fig. 4ba, bb).  
All of the KYNA derivatives had a time-dependent inhibitory effect (p < 0.05) on cell adhesion of GP8 cells at 
the highest concentration (10-3 mol/L) tested, whereas KYNA’s effects were neutral at this non-physiological 
concentration (Fig. 5 and Online Resource 1). KYNA-A1, KYNA-A2, KYNA-A4 and KYNA-A5 are amide 
derivatives. The KYNA-A1 analogue formed by coupling KYNA and 2-dimethylaminoethyl-amine (Nagy et al. 
2011) increased the attachment of GP8 cells with a lower activity (15 h: 114.6%, pcontrol = 0.081; KYNA-A1/10-9 
mol/L vs. KYNA/10-9 mol/L: p = 0.061) as compared to KYNA at a concentration of 10-9 mol/L (Fig. 5a). The 
adhesion enhancement effect of KYNA-A2, containing a heterocycle (2-pyrrolidinoethylamine) in the side chain 
(Nagy et al. 2011), was also lower (15 h: 116.7%, pcontrol = 0.019; KYNA-A2/10-7 mol/L vs. KYNA/10-9 mol/L: p 
= 0.045) and its activity was observed at a higher concentration (10-7 mol/L) compared to KYNA (Fig. 5b). 
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KYNA-A4 and KYNA-A5 differ from KYNA-A1; they contain a tertiary nitrogen in different ring systems as a 
second side chain at the C3 position (Demeter et al. 2012). Both KYNA-A4 and KYNA-A5 had neutral effects at the 
10-9-10-7 mol/L concentration range (Fig. 5c, d). 
 
3.3 Cell motion analysis 
Single cells (50 cells/field) were tracked in time-lapse videos created by the HoloMonitor M4 microscope in 
order to obtain detailed information (migration, motility and motility speed) regarding cell locomotion. For this 
cell-tracking experiment, KYNA was chosen since it had the most significant cell adhesion inducer effects in GP8 
cells. 
Based on the results of the tested parameters, KYNA decreased the movement of GP8 cells in both tested 
concentrations (10-9, 10-7 M) (Fig. 6; Table 2). The migration (distance) and the motility (actual path) of KYNA-
treated cells gradually decreased at the 2 h interval (migration: 10-9 M – 14.51 μm, p = 0.0026; 10-7 M: 16.80 μm, 
p = 0.0011; motility: 10-9 M – 146.48 μm, p = 0.0012; 10-7 M: 153.48 μm, p = 0.0013) compared to the control 
cells (migration: 18.36 μm; motility: 192.16) (Fig. 6a, b; Table 2). The motility speed was rather constant during 
this time frame (Fig. 6c; Table 2).  
 
3.4 Morphometry 
The time-lapse recordings provided several different morphological parameters (basic and complex ones; see 
the list and the definitions in section 2.4 Digital holographic microscopy), allowing for additional information on 
adhesion measurements and for analysis of viability. 
The observed changes in the basic parameters (area, thickness and volume) (Online Resource 2) corresponded 
well with the adhesion inducer effects of KYNA. Due to the treatment (10-7 mol/L), the mean area was slightly 
but significantly larger (257.8 μm2, p = 0.0032) and in parallel, the mean average thickness (2.17 μm, p = 0.023) 
was smaller than that of the control (area: 243.9 μm2, thickness: 2.31 μm); these changes indicated an increase in 
the spreading of the treated cells (Online Resource 2). KYNA induced changes in two complex morphological 
parameters, irregularity and roughness (as viability markers). A healthy cell is characterised by lower roughness 
and higher irregularity, while a dying or dead cell has higher roughness and lower irregularity. There was an 
increase in the mean irregularity (0.42, p = 0.0047) and a decrease in the mean roughness (4.24, p = 0.00205) of 
KYNA (10-9 mol/L) of treated cells compared to that of the control (irregularity: 0.39, roughness: 4.68). KYNA 
failed to have any effect on the other observed parameters (volume, eccentricity, hull convexity) (Online Resource 
2). 
 
4. Discussion 
In several CNS diseases, stimulation of the re-endothelization process is considered to be a promising 
approach towards the treatment or prevention of these pathological conditions (del Zoppo and Milner 2006; Lyros 
et al. 2014; Persidsky et al. 2006). Some clinically used pharmacological agents (e.g. statins, angiotensin-
converting-enzyme inhibitor) have been shown to enhance endogenous re-endothelization capacity. These drugs 
can improve endothelial repair through various mechanisms including: (i) increasing the number of circulating 
endothelial progenitor cells through mobilization from the bone marrow; (ii) inducing of endothelial proliferation, 
differentiation and migration; and (iii) enhancement of adhesiveness of endothelial cells by upregulation of the 
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expression of different cell adhesion molecules (e.g. β1-, β5-integrins, selectins) (Besler et al. 2008; Zampetaki et 
al. 2008).  
KYNA and its synthetic analogues have been found to have therapeutic value in different neurological 
disorders due to their neuroprotective and anti-inflammatory activity (Vecsei et al. 2013). In the present work, our 
main purpose was to investigate the action of KYNA on GP8 endothelial cell behaviour and morphology and to 
compare the adhesion modulator effects of different synthetic KYNA derivatives. 
For detailed characterization of a candidate drug, the kinetic analysis of cell physiological responses and of 
morphological changes by non-invasive and label-free methods (such as holographic microscopy or impedance 
based techniques) represents a powerful approach.  
Based on our results, KYNA itself was most effective in enhancing adhesion at 10-9 and 10-7 mol/L 
concentrations, which are well correlated to physiological levels (the plasma concentration of KYNA is 30-50 
nmol/L ~ 3-5 x 10-8 mol/L (Mandi and Vecsei 2012)). This adhesion inducer effect was well correlated with 
morphometry measurements done by holographic microscope. The morphological parameters indicated greater 
spreading of GP8 cells, which could explain the increased impedance and adhesion detected by the xCELLigence 
system. Based on the results of the morphometry (e.g. thickness, eccentricity irregularity), it could also be 
concluded that the KYNA did not have toxic effects; the cells showed typical flat and elongated shape during the 
time interval (Antal et al. 2014; Tóth et al. 2014). It was also shown by cell tracking that KYNA caused a slow 
and random movement of the GP8 cells, resulting in a decreased motility (actual path) and migration (shortest 
distance). This effect can be beneficial with respect to resting endothelium in order be able to stabilize the cell-
ECM and cell-cell junctions; while for endothelial repair, high endothelial motility seems to be important and 
involves the migration of cells as a cohesive group rather than as individual cells. In our study, individual cells 
were monitored and thus, their individual migration cannot be considered as a clear indication of migratory 
response of the entire cell population. Based on a previously reported wound-healing assay accomplished using 
the Holomonitor M4 microscope, it is assumed that in a cell population, the effects of KYNA could be different 
depending on the cell number and on the position of cells in a monolayer (Phase Holographic Imaging PHI AB 
2015). The link between KYNA and the endothelium has been previously investigated by Pawlak et al. In their 
studies, KYN metabolites generated by endothelial cells were shown to associate with endothelial dysfunction 
markers (e.g. increased serum level of circulating sICAM-1, sVCAM-1 adhesion molecules) and with the oxidative 
status of endothelial cells in patients having chronic kidney disease who were at high risk for atherosclerotic 
cardiovascular disease (Pawlak et al. 2009; Pawlak et al. 2010). From these studies, cause and effect could not be 
determined; nevertheless, the protective role of KYNA on vascular endothelium is believed to be likely. The 
endothelium seems to be an important source of KYNA (Stazka et al. 2002). The different risk factors (e.g. 
hyperhomocysteinemia) for endothelial dysfunction affect the endothelial production of KYNA in both in vitro 
and in vivo (Pawlak et al. 2010; Stazka et al. 2005). Moreover, KYNA has shown to offer protection against 
hyperhomocysteinemia-caused endothelial damage (Wejksza et al. 2009).  
Our results have raised the question concerning the molecular mechanisms underlying the effects of KYNA 
and the need to study how the observed changes in endothelial function are mediated throughout. Nevertheless, 
we would like to suggest some potential mechanisms that may explain the effects of KYNA. Several types of 
glutamate receptors, including NMDA receptors, have been demonstrated to be expressed on brain endothelial 
cells (Krizbai et al. 1998). These receptors are involved in the glutamate-induced hyper-permeability of the BBB 
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as well as alteration in the expression, distribution and phosphorylation of a tight junction protein, the occludin 
(Andras et al. 2007). Oláh et al. reported that KYNA as an NMDA receptor antagonist could reduce BBB 
permeability similarly to that of the positive reference compound, an NMDA receptor blocker (Oláh et al. 2013). 
These results indicate that KYNA might induce endothelial cell adhesion by regulating the expression of adhesion 
molecules either directly, or via NMDA receptors. The potential role of cell adhesion molecules in the actions of 
KYNA is further supported by a former study in an in vitro vascular flow model. It was reported that KYNA 
triggered the firm adhesion of monocytes to both fibronectin and ICAM-1 via β1 integrin- and β2 integrin-mediated 
mechanisms with activation of GPR35 (Barth et al. 2009). 
Our current results regarding the most significant adhesion inducer activity of KYNA occurring at nanomolar 
concentrations appears to be compatible with the former theory such that KYNA in the concentration range 
between a nanomolar and micromolar displays different effects. This Janus-face activity could be explained by 
the presence of different receptors/binding sites with different affinity and the induction of different mechanisms 
(e.g. antagonist for glycine-site of NMDA receptor: IC50 = 0.01 – 10 μM and agonist for GPR35: EC50 = 0.1 - 
30 μM) (Cosi et al. 2011; Moroni et al. 2012; Rozsa et al. 2008). The time-dependent effects of KYNA on 
endothelial cells are consistent with other studies, indicating the rapid up-regulation and long-term down-
modulation of immune response induced by KYNA (Barth et al. 2009). In our adhesion measurements, the 
increasing effects of KYNA, as time elapsed, could be due to its possible effects on the de novo synthesis and 
expression of adhesion molecules. Based on our results, the effects of KYNA could also be advantageous in the 
cerebral endothelium through preservation of the integrity of both the endothelium and BBB. By facilitating the 
adhesion of endothelial cells, KYNA may play a role in endothelial repair mechanisms in the case of 
neurodegenerative and neuroinflammatory diseases. These results pave the way for further studies to help clarify 
the potential role of KYNA in the homeostasis of endothelium.  
Interestingly, the precursor molecule KYN proved to be ineffective as a cell adhesion modulator. Once the 
KYN is locally synthesized or taken up from the blood, it can be further metabolized to KYNA by irreversible 
transamination (Vecsei et al. 2013). Therefore, KYN can be protective to the cerebral endothelial cells because it 
can be considered as a prodrug of KYNA (Vecsei et al. 2013).  
Comparing our present findings on endothelial cells to our preliminary results (as yet unpublished) on two 
murine mammary tumour cell lines (LM2 and LM3) having different metastatic capabilities, it is suggested that 
the cell adhesion modulator activity of KYNA and KYN appears to be dependent on cell type, or on the invasive 
capacity of the cells. Both compounds had neutral effects in non-metastatic LM2 cells, while in the case of the 
metastatic LM3 cell line, KYN slightly increased cell adhesion and KYNA decreased it. Based on these 
impedance-based measurements, we may be able to exclude the possibility that KYNA exerts some unknown 
influence and induces morphological changes irrespective of cell type. Nevertheless, further studies need to be 
undertaken which can take into account, for example, intracellular [Ca2+] or the changes of cytoskeleton. 
KYNA is produced both in the brain and in peripheral tissues (e.g. heart (Baran et al. 1997), vasculature 
(Stazka et al. 2002), immune cells (Mandi and Vecsei 2012)). Because KYNA has limited ability to cross the BBB, 
only the neuroprotective effects of locally synthesized KYNA can be taken into account in the CNS. The systemic 
administration of KYNA as a neuroprotective agent is restricted and indirect pharmacological approaches are 
needed to exploit its therapeutic potential (Nagy et al. 2011). Accordingly, several new KYNA analogues have 
been designed. KYNA amides synthesized in our laboratory are promising candidates because they have similar 
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neuroprotective activity compared to KYNA (e.g. selective inhibition of NMDA receptors (Nagy et al. 2011), they 
protect against epileptiform seizures (Demeter et al. 2012), they diminish hippocampal cell loss and preserve long-
term potentiation (Fülöp et al. 2012)). In the present work, different KYNA amides were studied with respect to 
endothelial cell adhesion. These KYNA amides were formed through transformation of the 2-carboxylic function 
of KYNA with a (i) water-soluble side-chain containing a (ii) new cationic center with (iii) side-chain substitution 
enhancing penetration into the brain.  
According to the results of the KYNA derivatives, the original moieties at the C2 and C3 positions of KYNA 
seem to be required for cell adhesion inducer activity. The substitution of KYNA with a single amide side chain 
of C2-carboxylic function in KYNA-A1 and KYNA-A2 has reduced cell adhesion inducer ability of the parent 
drug. However, the positive effects of KYNA-A1 and KYNA-A2 shows that they could contribute to maintenance 
or restoration of the integrity of the cerebral endothelium. It has been demonstrated that the substitution of a side-
chain at the C2 position enhances penetration of these compounds through the BBB (Nagy et al. 2011), whose 
properties also support the therapeutic significance of their adhesion enhancer effects. KYNA-A4 and KYNA-A5, 
each having a side chain at position C3, had neutral effects on cell adhesion at physiological concentrations. In a 
recent study, it has been shown that the permeability of KYNA-A4 was remarkably high in an in vitro BBB model 
compared to that of other KYNA derivatives (Demeter et al. 2012). Considering our current results, it is possible 
that KYNA-A4 can cross the BBB without any alterations to the endothelial barrier, which has a potential 
significance with respect to clinical applications as a derivative non-harmful to endothelial cells.  
The strong adhesion decreasing effects of KYNA analogues on cell-ECM adhesion were observed at the 10-3 
mol/L concentration, whose effect cannot be considered as an unfavourable effect of endothelial structure or 
function. This millimolar concentration is much higher than the normal plasma level of KYNA and even higher 
than its substantially elevated concentration in different pathological conditions (e.g. inflammation) (Mandi and 
Vecsei 2012). The negative effects of KYNA derivatives at 10-3 mol/L give rise to the question as to whether the 
KYNA derivatives could decrease the viability of endothelial cells. Based on the real time data provided by the 
xCELLigence System, the cytotoxic/antiproliferative effects of KYNA derivatives can be excluded. This 
impedance-based assay is sensitive enough for cytotoxicity experiments. In the event of a cytotoxic compound, a 
drop in the CI value would be observed (Urcan et al. 2010). At high concentration, the decreased adhesion was 
followed by a plateau phase (between 5 and 15 h incubation) and later (after 15 h), a slow gradual increase in CI 
values, indicating proliferation of GP8 cells. We hope that further studies (e.g. measurements of adhesion protein 
expression and of morphometry with holographic microscope) will be able to explain the adhesion decreasing 
effects of KYNA derivatives. 
This in vitro study, in which cells of one type are exposed to fixed concentrations of KYNA and its analogues, 
is a first step towards understanding the potential effects of KYNA; however, our experimental setup has some 
limitations as a potential model that could simulate the in vivo conditions of the BBB. Firstly, in the establishment 
and maintenance of the BBB; other elements of the neurovascular unit (in addition to the brain microvascular 
endothelial cells) are involved, including astrocytes, pericytes, neurons and basal lamin (Persidsky et al. 2006). 
Secondly, the concentration of the administered KYNA can be dynamically modulated by different cells in the 
CNS. Endothelial cells and astrocytes were demonstrated as an important source of KYNA (Dantzer et al. 2008; 
Stazka et al. 2002); while, for example, macrophages and microglia can uptake and metabolize KYN to form other 
types of kynurenines instead of KYNA (Vecsei et al. 2013). Blood flow can also dilute concentrations of KYNA 
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produced locally. It should also be considered that different disease states could significantly influence KYNA 
concentrations, the functions of the BBB and endothelial cells. During inflammation (Mandi and Vecsei 2012) and 
in Alzheimer’s disease (Dezsi et al. 2015), it was found that there is an enhanced degradation of tryptophan in 
parallel with an increase in KYNA. Thus, in order to predict the therapeutic significance of KYNA, it could be 
interesting to investigate the effects of KYNA and its analogues on endothelial cells in a laminar flow environment, 
as well as on other cell types of the neurovascular unit (e.g. astrocytes). Future work should also rely on a model 
that takes inflammatory and endothelial damage conditions into account, and could also represent a more suitable 
system for investigating the effects of KYNA as a potential drug that promotes endothelial repair. Such a model 
would surely require a preceding study on a basal/quiescent state of endothelial cells such as ours.  
According to our data, kynurenines may be able to modulate the complex function of neurovascular unit by 
influencing cell-ECM adhesion and thus, they offer a new therapeutic option for diseases relating to dysfunction 
of the BBB.  
 
5. Conclusions 
In summary, based on our results, GP8 brain endothelial cells can be successfully used as a sensitive model 
in order to study the effects of KYNA derivatives (or other types of neuropharmacological drugs) on cell adhesion, 
morphology and movement. The results obtained on endothelial responses indicate that cell-ECM adhesion and 
locomotion of brain endothelial cells could be a new therapeutic target of KYNA and its amide derivatives. Based 
on their adhesion inducer effects, these compounds (KYNA, KYNA-A1 and A2) could play a potential role in 
facilitating endothelial repair and in maintaining the endothelial integrity of the BBB in different neurological 
disorders. However, in order to firmly assess this hypothesis, further experiments are needed to be able to clarify 
the molecular background behind the action of KYNA derivatives; they are also needed in order to investigate the 
influence of these compounds on other elements of the neurovascular unit, and in a model that takes endothelial 
dysfunction/damage into account. Nevertheless, our measurements with impedimetric and holographic methods 
suggest that these novel label-free biosensing methods can be especially useful for conducting high content 
analyses of the effects of a candidate drug on cell behaviour and morphology. 
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Tables 
Table 1 Empirical formula and analytical parameters of investigated synthetic kynurenic acid analogues 
Name 
Empirical 
formula 
Molecular 
weight 
(g/mol) 
Melting point 
(°C) ≈ 
Dissolve 
H2O 
Kynurenic acid (KYNA) C10H7NO3 189.17 282-283 + 
L-kynurenine (KYN) C10H12N2O3 208.21 302 + 
KYNA-A1 C14H18ClN3O2 295.76 178-180 + 
KYNA-A2 C16H20ClN3O2 321.80 227-230 + 
KYNA-A4 C19H26N4O3 358.20 >350 
+ 
(< 10-3 M) 
KYNA-A5 C19H26N4O2 342.21 >350 
+ 
(< 10-3 M) 
Kynurenic acid derivatives – amides of C2-carboxylic function (KYNA-A1 and -A2) and amides of C2-
carboxylic function + side chains on C3 (KYNA-A4 and -A5) 
 
 
Table 2 Effect of KYNA on GP8 endothelial cell movement detected by holographic microscopy 
Parameters Control KYNA 10-9 mol/L KYNA 10-7 mol/L 
Avg. Migration (μm) 18.36 ± 5.01 14.51 ± 3.59 ** 16.80 ± 4.52 ** 
Avg. Motility (μm) 192.16 ± 56.32 146.48 ± 41.62 ** 153.48 ± 42.89 ** 
Avg. Motility speed (μm/h) 94.52 ± 14.28 72.67 ± 9.93 * 76.25 ± 13.46 * 
Data represent averages (Avg.) and ±S.D. values calculated for 50 cell/group in 240 consecutive frames.  
The presented data were calculated by HoloStudioTM M4 2.5 and analysed by Origin Pro 8.0. 
The levels of significance are shown as follows: *: p<0.05; **: p<0.01 
  
19 
 
Legends of tables 
Table 1 Empirical formula and analytical parameters of investigated synthetic kynurenic acid analogues 
Kynurenic acid derivatives – amides of C2-carboxylic function (KYNA-A1 and -A2) and amides of C2-
carboxylic function + side chains on C3 (KYNA-A4 and -A5) 
 
Table 2 Effect of KYNA on GP8 endothelial cell movement detected by holographic microscopy 
Data represent averages (Avg.) and ±S.D. values calculated for 50 cell/group in 240 consecutive frames. 
The presented data were calculated by HoloStudioTM M4 2.5 and analysed by Origin Pro 8.0. 
The levels of significance are shown as follows: *: p<0.05; **: p<0.01. 
 
 
Legends of figures 
Fig. 1 Tryptophan-kynurenine metabolism 
TDO/IDO, tryptophan- or indoleamine 2,3-dioxygenases-1 and -2; KAT, kynurenine aminotransferase 
 
Fig. 2 Role of cell adhesion in maintenance of endothelial integrity 
The endothelium can become dysfunctional in certain pathological condition (e.g. neurodegeneration), which can 
progress to senescence and detachment of endothelial cells. The endogenous repair processes can restore 
endothelial integrity. The neighbouring endothelial cells can proliferate and adhere to the injury; the incorporation 
of circulating endothelial progenitor cells can also ensure re-endothelization. 
ICAM-1, Intercellular Adhesion Molecule 1; HMGB1, High-Mobility Group protein B1; PSGL-1, P-Selectin 
Glycoprotein Ligand-1, VEGF, Vascular Endothelial Growth Factor; SDF-1, Stromal cell-Derived Factor 1. 
 
Fig. 3 Characterization of adhesion properties of GP8 endothelial cells 
Time course study (a) and slope analysis (b) of the adhesion measurement by xCELLigence SP System. 
The Delta CI (Delta Cell index) refers to the difference of the CI value at the point in time of cell inoculation and 
the CI value at another given point in time. The slope values are expressed as a percentage of the control and 
describe the changing rate of Delta CI in a 3 hour time interval (between the point in time of cell inoculation and 
the point in time resulting in a maximum of cell adhesion). Data shown in the figures represent mathematical 
averages of three parallels and ±SD values. The levels of significance are shown as follows * – p<0.05. 
 
Fig. 4 Effects of KYNA and KYN on cell adhesion of GP8 endothelial cells 
Time course study of cell adhesion modulator effects of  KYNA (aa) and KYN (ba) as well as statistical evaluation 
of the effect of KYNA (ab) and KYN (bb) at individual time points (5, 10 and 15 h). 
The Delta CI (Delta Cell index) refers to the difference of the CI value at the point in time of cell inoculation and 
the CI value at another given point in time. The Norm. Delta CI (Normalized Delta Cell index) values were 
calculated at individual time points (5, 10 and 15 h), and were normalized to the control (control=100%). Data 
shown in the figures represent mathematical averages of three parallels and ±SD values. The levels of significance 
are shown as follows: * – p<0.05; ** – p<0.01. 
KYNA – kynurenic acid, KYN – L-kynurenine 
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Fig. 5 Effects of KYNA amides (KYNA-A1, -A2, -A4 and –A5) on cell adhesion of GP8 endothelial cells 
The Norm. Delta CI (Normalized Delta Cell index) values were calculated at individual time points (5, 10 and 15 
h) and were normalized to the control (control=100%). Data shown in the figures represent mathematical averages 
of three parallels and ±SD values. The levels of significance are shown as follows * – p<0.05; ** – p<0.01; *** – 
p<0.001. 
KYNA – kynurenic acid; KYNA derivatives – amides of C2-carboxylic function (KYNA-A1 and -A2) and 
amides of C2-carboxylic function + side chains on C3 (KYNA-A4 and -A5) 
 
Fig. 6 Cell locomotory responses of GP8 endothelial cells induced by KYNA 
Measurements of migration (a); motility (b); motility speed (c) by holographic microscopy. 
Data shown in the figures represent averages (Avg.) and ±S.D. values calculated for 50 cell/group in 240 
consecutive frames. 
KYNA – kynurenic acid 
 
 
